How we can mitigate the side effects associated with systemic glucocorticoid after allogeneic hematopoietic cell transplantation

Shigeo Fuji*, Michael Byrne, Arnon Nagler, Mohamad Mohty, Bipin N. Savani

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations

Abstract

Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment for patients with a hematologic disease. Although the clinical outcomes after allo-HCT have significantly improved during the last few decades, graft-versus-host disease (GVHD) is still a major cause of post-HCT morbidity and mortality. Systemic glucocorticoids (GC) remain an integral part of treatment in patients with GVHD including both acute and chronic GVHD. Although it is well-known that usage of systemic GC is associated with various side effects, the short- and long-term effects of GCs in the HCT setting are not well-characterized due to limited published data. In order to clarify this issue, we summarize the information on side effects associated with GCs, focusing specifically on the sequelae of these agents in the early post-HCT period. In instances where limited data are available, we included data from other fields such as autoimmune diseases, given the potential parallels between autoimmune conditions and GVHD.

Original languageEnglish
Pages (from-to)1248-1256
Number of pages9
JournalBone Marrow Transplantation
Volume56
Issue number6
DOIs
StatePublished - Jun 2021

Funding

FundersFunder number
Health, Labour and Welfare Sciences Research Grants20FF1002

    Fingerprint

    Dive into the research topics of 'How we can mitigate the side effects associated with systemic glucocorticoid after allogeneic hematopoietic cell transplantation'. Together they form a unique fingerprint.

    Cite this